These findings suggest that in COPD treatment, the relative abundance of Halomonas and Nesterenkonia are increased by decreasing the relative abundance of Mycoplasma, potentially inhibiting the inflammatory factors IL-1β, TNF-α, IL-6, IL-1β, and TGF-β1. The gene discussed is IL1B; the disease is chronic obstructive pulmonary disease.